Furthermore, increased G/GM‐CSF levels are confirmed to be highly correlated with poor prognosis and tumor staging in cancers such as lung cancer, glioma, colorectal cancer, melanoma, breast, and bladder cancers [15]. This evidence concerns the gene CSF2 and melanoma.